| Autor: |
Jing Tang, Xuqian Ma, Xin Chen, Mingqian Feng, Xin Jin, Ke Wang, Jixi Wan, Xianmin Zhu, Rong Xie, Shuang Dong, Sheng Hu, Hui Jiang, Conghua Xie |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Annals of translational medicine. 10(14) |
| ISSN: |
2305-5839 |
| Popis: |
For programmed cell death protein 1/programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC), the addition of immune checkpoint inhibitors (ICIs) to chemotherapy has been shown to increase the objective response rate (ORR) by only 13.4-16.3%. Thus, examining converting tumor immunogenicity and targeting novel pathways may be needed to improve response to immunotherapy. B7-H4 is an emerging target for breast cancer immunotherapy. However, the antitumor effect of B7-H4 is unstable during cell generation and further research is necessary to strengthen the antitumor efficacy of B7-H4.To explore the potential of B7-H4-targeted immunotherapy of breast cancer, current study generated four monoclonal antibodies (mAbs) against B7-H4 through immunization of mice followed by phage display technology. T cell-engaged bispecific antibodies and immunotoxins were created based on these mAbs. To evaluate the anti-tumor activity of B7-H4-targeting bispecific antibody and immunotoxin, the anti-tumor efficacy testRigorousCollectively, our findings uncover a novel strategy of combining oncolytic virus HSV-2 with bispecific antibody reinforce antitumor immune response, which warranted further translational investigation. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
